相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Discovery of second generation heat shock protein 110 (HSP110) inhibitors for potential treatment of colorectal cancer
Li Xu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY REPORTS (2023)
Discovery and SAR analysis of 5-chloro-4-((substituted phenyl)amino)pyrimidine bearing histone deacetylase inhibitors
Lin Zhang et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2022)
Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019)
Xingrui He et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2020)
The histone deacetylase HDAC1 activates HIF1α/VEGFA signal pathway in colorectal cancer
Cheng Chen et al.
GENE (2020)
Y Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective
Yuan Gao et al.
BIOCHEMICAL PHARMACOLOGY (2020)
A novel class of anthraquinone-based HDAC6 inhibitors
Yoojin Song et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Drugs Targeting Epigenetic Modifications and Plausible Therapeutic Strategies Against Colorectal Cancer
Srinivas Patnaik et al.
FRONTIERS IN PHARMACOLOGY (2019)
Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity
Fan Yun et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Therapeutic potential of selective histone deacetylase 3 inhibition
Lihui Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
7-Azaindole: A Versatile Scaffold for Developing Kinase Inhibitors
Takayuki Irie et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2018)
Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat
Lianbin Yao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016)
Peng Zhan et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2017)
Pyrazolo[1,5-a]pyrimidine-based macrocycles as novel HIV-1 inhibitors: a patent evaluation of WO2015123182
Lin Sun et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2016)
STRUCTURAL BIOLOGY HDAC6 finally crystal clear
Yanli Liu et al.
NATURE CHEMICAL BIOLOGY (2016)
Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma
Sarah L. Greig
TARGETED ONCOLOGY (2016)
Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
Armin Rashidi et al.
FUTURE ONCOLOGY (2015)
Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy
Lei Zhang et al.
MEDICINAL RESEARCH REVIEWS (2015)
Multicomponent Synthesis of the Medicinally Important Pyrrolo[2,3-d]Pyrimidine Scaffold (Minireview)
R. Dasari et al.
CHEMISTRY OF HETEROCYCLIC COMPOUNDS (2014)
Conformational restriction: an effective tactic in 'follow-on'-based drug discovery
Zengjun Fang et al.
FUTURE MEDICINAL CHEMISTRY (2014)
Inhibition of HDAC6 Deacetylase Activity Increases Its Binding with Microtubules and Suppresses Microtubule Dynamic Instability in MCF-7 Cells
Jayant Asthana et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Development and therapeutic impact of HDAC6-selective inhibitors
Sabrina Dallavalle et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity
Zhi-Qiang Ning et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Vemurafenib: the first drug approved for BRAF-mutant cancer
Gideon Bollag et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Macrocyclic Peptoid-Peptide Hybrids as Inhibitors of Class I Histone Deacetylases
Christian A. Olsen et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer
Jaeku Kang et al.
CANCER RESEARCH (2011)
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
Cliona Grant et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2010)
Strategies in Developing Promising Histone Deacetylase Inhibitors
Lei Zhang et al.
MEDICINAL RESEARCH REVIEWS (2010)
Isoform-selective histone deacetylase inhibitors
Anton V. Bieliauskas et al.
CHEMICAL SOCIETY REVIEWS (2008)
Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer:: a retrospective analysis
Wilko Weichert et al.
LANCET ONCOLOGY (2008)
Expression of hypoxia-inducible factor-1α, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma
Kotaro Miyake et al.
PANCREAS (2008)
Effects of topical administration of Y-39983, a selective Rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys
Hideki Tokushige et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2007)
Discovery and development of SAHA as an anticancer agent
P. A. Marks
ONCOGENE (2007)
Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma
Tatsuya Rikimaru et al.
ONCOLOGY (2007)
Differential expression of selected histone modifier genes in human solid cancers
Hilal Ozdag et al.
BMC GENOMICS (2006)
Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast
ZH Zhang et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Structure-based design of novel Chk1 inhibitors: Insights into hydrogen bonding and protein-ligand affinity
N Foloppe et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Upregulation and nuclear recruitment of HDACI in hormone refractory prostate cancer
K Halkidou et al.
PROSTATE (2004)
Histone deacetylase 1 mRNA expression in lung cancer
H Sasaki et al.
LUNG CANCER (2004)
HDAC6 expression is correlated with better survival in breast cancer
ZH Zhang et al.
CLINICAL CANCER RESEARCH (2004)
Histone deacetylases (HDACs): characterization of the classical HDAC family
AJM De Ruijter et al.
BIOCHEMICAL JOURNAL (2003)
HDAC6 is a microtubule-associated deacetylase
C Hubbert et al.
NATURE (2002)
分享论文
